II. Preparations (Norethindrone Acetate / Ethinyl Estradiol)

  1. Estrostep (1 / 20 - 30 - 35)

III. Components

  1. Norethindrone Acetate 1 mg (see preparation above)
  2. Ethinyl Estradiol 20 ug - 30 ug - 35 ug

IV. Effects

  1. Relative Progestational Activity: 1.2 (high)
  2. Estrogenic Activity: 16 (low)
  3. Androgenic Activity: 0.53 (high)

V. Pill associated problems

  1. Indications to switch to Ortho Novum 1/35
    1. Acne Vulgaris (lower androgen)
  2. Indications to switch to Ortho Cyclen
    1. Increased Appetite (lower Progestin)
    2. Major Depression provoked (lower Progestin)
  3. Indications to switch to Lo/Ovral
    1. Break-through bleed days 1-9 (more Estrogen)
    2. Break-through bleed all of month (more Estrogen)
    3. Menses too light (more Estrogen, less Progestin)
  4. Indications to switch to Loestrin 1.5/30
    1. Libido decreased (more androgen)
    2. Break-through bleed days 10-21 (more Progestin)
    3. Heavy Menses (more Progestin or less Estrogen)
    4. Dysmenorrhea or Menstrual Cramps (more Progestin)
  5. Indications to switch to Loestrin 1/20
    1. Breast Tenderness or engorgement (lower Estrogen)
    2. Headaches (lower Estrogen)
    3. Moodiness (less Estrogen or more Progestin)
    4. Weight gain (less Estrogen or more Progestin)

VI. References

Images: Related links to external sites (from Bing)

Related Studies (from Trip Database) Open in New Window

Ontology: Estrostep (C0116660)

Concepts Pharmacologic Substance (T121) , Steroid (T110)
MSH C020416
English estrostep, Estrostep